A response rate of 29.7% was reported for pembrolizumab treatment of BM in patients with programmed cell death-ligand 1 (PD-L1)-positive non-small cell lung cancer (NSCLC) [1]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.